Equities research analysts expect Affimed NV (NASDAQ:AFMD) to post sales of $6.46 million for the current quarter, according to Zacks. Two analysts have issued estimates for Affimed’s earnings, with estimates ranging from $6.13 million to $6.79 million. Affimed reported sales of $180,000.00 in the same quarter last year, which indicates a positive year over year growth rate of 3,488.9%. The business is expected to announce its next earnings results on Wednesday, August 14th.
On average, analysts expect that Affimed will report full year sales of $36.57 million for the current year, with estimates ranging from $13.00 million to $87.20 million. For the next year, analysts forecast that the business will post sales of $65.34 million, with estimates ranging from $1.00 million to $169.00 million. Zacks Investment Research’s sales averages are an average based on a survey of sell-side analysts that that provide coverage for Affimed.
Affimed (NASDAQ:AFMD) last announced its quarterly earnings data on Wednesday, May 22nd. The biopharmaceutical company reported $0.03 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.16) by $0.19. Affimed had a negative return on equity of 23.61% and a negative net margin of 29.04%. The company had revenue of $12.89 million for the quarter, compared to analysts’ expectations of $6.77 million.
Several analysts have issued reports on AFMD shares. ValuEngine raised Affimed from a “hold” rating to a “buy” rating in a research report on Wednesday, March 20th. Zacks Investment Research cut Affimed from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, April 2nd. Svb Leerink started coverage on Affimed in a research report on Thursday, March 28th. They set an “outperform” rating and a $8.00 target price on the stock. Finally, Leerink Swann started coverage on Affimed in a research report on Thursday, March 28th. They set an “outperform” rating and a $4.17 target price on the stock. Two equities research analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. Affimed has a consensus rating of “Buy” and a consensus target price of $4.99.
NASDAQ AFMD traded up $0.14 during midday trading on Friday, hitting $3.10. 1,133,310 shares of the company traded hands, compared to its average volume of 751,537. The company has a current ratio of 3.17, a quick ratio of 3.16 and a debt-to-equity ratio of 0.03. The stock has a market capitalization of $163.46 million, a PE ratio of -8.16 and a beta of 3.08. Affimed has a 52 week low of $1.40 and a 52 week high of $7.35.
A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Wellington Management Group LLP boosted its position in Affimed by 0.8% during the 1st quarter. Wellington Management Group LLP now owns 4,730,733 shares of the biopharmaceutical company’s stock valued at $19,869,000 after acquiring an additional 36,690 shares in the last quarter. Millennium Management LLC raised its stake in Affimed by 7.2% in the 4th quarter. Millennium Management LLC now owns 3,121,914 shares of the biopharmaceutical company’s stock worth $9,709,000 after acquiring an additional 210,884 shares during the last quarter. Stonepine Capital Management LLC purchased a new position in Affimed in the 4th quarter worth $2,221,000. Telemetry Investments L.L.C. raised its stake in Affimed by 127.9% in the 4th quarter. Telemetry Investments L.L.C. now owns 425,398 shares of the biopharmaceutical company’s stock worth $1,323,000 after acquiring an additional 238,719 shares during the last quarter. Finally, Sio Capital Management LLC raised its stake in Affimed by 65.8% in the 1st quarter. Sio Capital Management LLC now owns 267,942 shares of the biopharmaceutical company’s stock worth $1,125,000 after acquiring an additional 106,307 shares during the last quarter. 37.50% of the stock is currently owned by institutional investors and hedge funds.
Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Europe, and Germany. Its lead product candidate is AFM13, a natural killer cell (NK-cell) TandAb, which is in Phase 2a clinical study of relapsed CD30-positive lymphoma and Phase 1b clinical study of anti-PD-1 antibody Keytruda (pembrolizumab) in patients with relapsed Hodgkin lymphoma.
Read More: Price to Earnings Ratio (PE) Basics
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Affimed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Affimed and related companies with MarketBeat.com's FREE daily email newsletter.